blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2898923

EP2898923 - Isoflavones for regulating sirtuin gene expression [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  09.03.2018
Database last updated on 02.09.2024
FormerExamination is in progress
Status updated on  14.12.2016
Most recent event   Tooltip09.03.2018Application deemed to be withdrawnpublished on 11.04.2018  [2018/15]
Applicant(s)For all designated states
Nestec S.A.
Avenue Nestlé 55
1800 Vevey / CH
[2017/42]
Former [2015/31]For all designated states
Nestec S.A.
Avenue Nestlé 55
1800 Vevey / CH
Inventor(s)01 / Pan, Yuanlong
2743 Quail Valley Drive
Chesterfield, MO Missouri 63017 / US
02 / Middleton, Rondo, Paul
12366 Country Glen Lane
Creve Coeur, MO Missouri 63141 / US
 [2015/31]
Representative(s)Rupp, Christian
Mitscherlich PartmbB
Patent- und Rechtsanwälte
Karlstraße 7
80333 München / DE
[N/P]
Former [2015/31]Rupp, Christian
Mitscherlich PartmbB
Patent- und Rechtsanwälte
Sonnenstraße 33
80331 München / DE
Application number, filing date15158963.726.03.2012
[2015/31]
Priority number, dateUS201161517228P15.04.2011         Original published format: US 201161517228 P
[2015/31]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2898923
Date:29.07.2015
Language:EN
[2015/31]
Type: A3 Search report 
No.:EP2898923
Date:07.10.2015
Language:EN
[2015/41]
Search report(s)(Supplementary) European search report - dispatched on:EP04.09.2015
ClassificationIPC:A61P25/28, A61K31/353, A23L1/30, A61K31/70
[2015/31]
CPC:
A61K31/70 (EP,RU,US); A61K31/353 (RU,US); A23L33/105 (EP,US);
A61P25/28 (EP); A61P3/04 (EP); A61P39/06 (EP);
A61P43/00 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/20]
Former [2015/31]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:Isoflavone zur Regulierung der Sirtuin-Genexpression[2015/31]
English:Isoflavones for regulating sirtuin gene expression[2015/31]
French:Isoflavones pour la régulation de l'expression d'un gène sirtuine[2015/31]
Examination procedure05.04.2016Amendment by applicant (claims and/or description)
05.04.2016Examination requested  [2016/20]
27.07.2016Despatch of a communication from the examining division (Time limit: M06)
08.12.2016Reply to a communication from the examining division
22.08.2017Despatch of a communication from the examining division (Time limit: M02)
03.11.2017Application deemed to be withdrawn, date of legal effect  [2018/15]
29.11.2017Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2018/15]
Parent application(s)   TooltipEP12770611.7  / EP2696692
Fees paidRenewal fee
13.03.2015Renewal fee patent year 03
13.03.2015Renewal fee patent year 04
10.03.2016Renewal fee patent year 05
10.03.2017Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]US5733926  (GORBACH SHERWOOD L [US]) [X] 1-15 * abstract * * claims 1-10 * * column 1, lines 40-47 *;
 [X]US2006002914  (MILBRANDT JEFFREY [US], et al) [X] 1-15 * claims 1,2,21 * * paragraphs [0013] , [0051] , [0049] , [0050] * * example 7 *;
 [X]US2008108696  (BRINTON ROBERTA D [US], et al) [X] 1-15 * claims 1,2 * * paragraphs [0016] , [0072] , [0142] - [0144] - [0157] - [0162] *;
 [X]  - ZHAO LIQIN ET AL, "WHI and WHIMS follow-up and human studies of soy isoflavones on cognition", EXPERT REVIEW OF NEUROTHERAPEUTICS, FUTURE DRUGS, LONDON, GB, (20071101), vol. 7, no. 11, doi:10.1586/14737175.7.11.1549, ISSN 1473-7175, pages 1549 - 1564, XP009099785 [X] 1-15 * abstract * * page 1551, column 2, paragraph 3 - page 1552, column 1, paragraph 1 * * page 1556; table 2 *

DOI:   http://dx.doi.org/10.1586/14737175.7.11.1549
 [X]  - HENRY-VITRAC C ET AL, "Soy isoflavones as potential inhibitors of Alzheimer sz-amyloid fibril aggregation in vitro", FOOD RESEARCH INTERNATIONAL, ELSEVIER APPLIED SCIENCE, BARKING, GB, vol. 43, no. 8, ISSN 0963-9969, (20101001), pages 2176 - 2178, (20100729), XP027351297 [X] 1-15 * abstract * * figure 1 * * page 2178, column 1, paragraph 2 *
 [A]  - QUIDEAU S, "PLANT POLYPHENOLIC SMALL MOLECULES CAN INDUCE A CALORIE RESTRICTION-MIMETIC LIFE-SPAN EXTENSION BY ACTIVATING SIRTUINS: WILL POLYPHENOLS SOMEDAY BE USED AS CHEMOTHERAPEUTIC DRUGS IN WESTERN MEDICINE?", CHEMBIOCHEM - A EUROPEAN JOURNAL OF CHEMICAL BIOLOGY, WILEY VCH, WEINHEIM, DE, (20040402), vol. 5, no. 4, doi:10.1002/CBIC.200300835, ISSN 1439-4227, pages 427 - 430, XP009057585 [A] 1 * page 428, paragraph 1 - column 3 * * page 427, column 3, paragraph 2 - page 428, column 1, paragraph 2 *

DOI:   http://dx.doi.org/10.1002/cbic.200300835
by applicantUS5952033
 US5968569
 US6929793
 EP1143806
 EP1296565
 EP1482811
 US7189390
 EP1213970
    - FINKEL ET AL., NATURE, (2009), vol. 460, pages 587 - 591
    - DONMEZ ET AL., CELL, (2010), vol. 142, pages 320 - 332
    - ASBACH ET AL., J PHARMACOL EXP THER, (2008), vol. 325, pages 536 - 543
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.